Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) announced that the company’s investigational Neuro-Spinal Scaffold has received the 2015 Becker’s Healthcare Spine Device Award. It is one of 25 devices that received this distinction from Becker’s Healthcare. According to their article, “Both ‘tried-and-true’ devices as well as new promising innovations are featured in this year’s awards.” Award nominees are determined by the publication’s editorial staff, in this case Becker’s Spine Review, and are vetted by a panel of industry experts.

Mark Perrin, InVivo Chief Executive Officer and Chairman, said, “We are very pleased to be receiving this notable award, especially from a publication as well respected as Becker’s Spine Review. I’d like to extend my gratitude to Becker’s for the recognition and to all of the members of the InVivo team for making this possible.”

Shares of Invivo Therapeutics Holdings Corp closed last Friday at $13.37 . NVIV has a 1-year high of $0 and a 1-year low of $0. The stock’s 50-day moving average is $12.92 and its 200-day moving average is $8.90.

On the ratings front, H.C. Wainwright analyst Andrew Fein initiated coverage with a Buy rating on NVIV and a price target of $25, in a report issued on April 20. The current price target represents a potential upside of 87.0% from where the stock is currently trading.

According to, Fein has a total average return of 23.8%, a 61.9% success rate, and is ranked #166 out of 3610 analysts.

InVivo Therapeutics Holdings Corp is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries.